Phase 2 study of zenocutuzumab (MCLA-128), a bispecific HER2/HER3 antibody in NRG1 fusion-positive advanced solid tumors Meeting Abstract
| Authors: | Schram, A.; Macarulla, T.; O'Reilly, E.; Rodon, J.; Wolpin, B.; Ou, S.; Kim, D.; Yang, J. C.; Lam, J.; De Langen, A.; Boni, V.; Cerea, G.; Duruisseaux, M.; Felip, E.; Liu, S.; O'Kane, G.; Senecal, F.; Nagasaka, M.; Starr, J.; Wasserman, E.; Drilon, A. |
| Abstract Title: | Phase 2 study of zenocutuzumab (MCLA-128), a bispecific HER2/HER3 antibody in NRG1 fusion-positive advanced solid tumors |
| Meeting Title: | 2020 World Conference on Lung Cancer |
| Keywords: | nrg1 fusion; bispecific her2/her3 antibody; zenocutuzumab (mcla-128) |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 16 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2021 Jan 28-31 |
| Meeting Location: | Singapore |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-03-01 |
| Start Page: | S675 |
| Language: | English |
| ACCESSION: | WOS:000631349602053 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.jtho.2021.01.1237 |
| Notes: | Meeting Abstract: P86.08 -- Due to Covid-19 pandemic, the conference was held virtually -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work